Abstract
The purpose of this study is to investigate the clinical relevance of deletion of ovarian carcinoma 2/disabled homolog 2 (DOC-2/DAB2) interacting protein (DAB2IP) expression in human urothelial carcinoma (UC). We studied DAB2IP protein expression by immunohistochemistry in 130 UCs (90 of the bladder and 40 of the upper urinary tract) and 79 adjacent normal tissues and assessed its prognostic value in terms of recurrence-free and progression-free survival in superficial bladder UC. Twelve human UC cell lines were examined for DAB2IP messenger RNA (mRNA) and protein expression using quantitative RT-PCR and western blotting. Selected cell lines were used to study the effect of treatment with chromatin-modifying agents (5-aza-2′-deoxycytidine, Trichostatin A, or both) on DAB2IP expression. Of 90 bladder tumors, 50 (56 %) and, of 40 upper tract UC, 11 (28 %) were positive for DAB2IP immunostaining (bladder cancer versus upper tract UC, p = 0.003). In 65 superficial cases of bladder cancer loss of DAB2IP, expression was significantly associated with decreased recurrence-free survival (p = 0.046), but not with progression-free survival. Most human urothelial cancer cell lines consistently express DAB2IP mRNA and protein, without any relation to S-phase kinase protein expression. After treatment with either 5-aza-2′-deoxycytidine or Trichostatin A or both, the low DAB2IP-expressing bladder cancer cell lines BFTC905 and BFTC909 showed increased DAB2IP mRNA expression. DAB2IP protein levels are higher in bladder cancer than in upper tract UC and in superficial bladder cancer. This is associated with longer recurrence-free survival. Epigenetic regulation of DAB2IP protein appears to play an important role in human urothelial carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. (2011) European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 59:584–594
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5:713–725
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, et al. (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158:929–944
Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009–1018
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59:997–1008
Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, et al. (2002) The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 27715:12622–12631
Chen H, Pong RC, Wang Z, Hsieh JT (2002) Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 79:573–581
Shen YJ, Kong ZL, Wan FN, Wang HK, Bian XJ, Gan HL, et al. (2014) Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer Sci 105:704–712
Tsai YS, Lai CL, Lai CH, Chang KH, Wu K, Tseng SF, et al. (2014) The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget 5:6425–6436
Jou YC, Tung CL, Tsai YS, Shen CH, Chen SY, Shiau AL, et al. (2009) Prognostic relevance of prothymosin-alpha expression in human upper urinary tract transitional cell carcinoma. Urology 74:951–957
Tsai YS, Jou YC, Lee GF, Chen YC, Shiau AL, Tsai HT, et al. (2009) Aberrant prothymosin-alpha expression in human bladder cancer. Urology 73:188–192
Chen H, Toyooka S, Gazdar AF, Hsieh JT (2003) Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 278:3121–3130
Dai X, North BJ, Inuzuka H (2014) Negative regulation of DAB2IP by Akt and SCFFbw7 pathways. Oncotarget 5:3307–3315
Aine M, Eriksson P, Liedberg F, Hoglund M, Sjodahl G (2015) On molecular classification of bladder cancer: out of one, many. Eur Urol 68:921–923
Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, Shapiro E, et al. (2007) Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 13:4400–4406
Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM, Thorgeirsson SS (2011) Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol 54:311–319
Zhou J, Hernandez G, Tu SW, Huang CL, Tseng CP, Hsieh JT (2005) The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res 65:9906–9913
Kunze E, Von Bonin F, Werner C, Wendt M, Schlott T (2006) Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements. Int J Mol Med 17:3–13
Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, et al. (2005) Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Can 92:1117–1125
Smits M, van Rijn S, Hulleman E, Biesmans D, van Vuurden DG, Kool M, et al. (2012) EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive marker for survival. Clin Cancer Res 18:4048–4058
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629
Chen H, Tu SW, Hsieh JT (2005) Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 280:22437–22444
Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, et al. (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16:286–294
Kong Z, Xie D, Boike T, Raghavan P, Burma S, Chen DJ, et al. (2010) Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Cancer Res 70:2829–2839
Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao GF, et al. (2013) The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res 19:4740–4749
Acknowledgments
This study was supported by the Chia-Yi Christian Hospital (Grants R102-20).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
The study was undertaken with the approval and institutional oversight of the Institutional Review Board for the Protection of Human Subjects at Chia-Yi Christian Hospital and National Cheng Kung University.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Jou YC and Tsai YS contributed equally
Rights and permissions
About this article
Cite this article
Jou, YC., Tsai, YS., Chen, SY. et al. Loss of DAB2IP expression in human urothelial carcinoma is associated with poorer recurrence-free survival. Virchows Arch 468, 733–740 (2016). https://doi.org/10.1007/s00428-016-1924-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-016-1924-y